EUVIMEDEUVIMED entdecken
Crossref

Neuroblastoma and Glioblastoma Cases With Amplified Oncogenes Have Reduced Numbers of Tumor-Resident Adaptive Immune Receptor Recombinations

Toriana R Dabkowski, Mallika Varkhedi, Joanna J Song iD, Etienne C Gozlan, George Blanck iD

JCO Precision Oncology · 2023

DOI: 10.1200/po.23.00057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Toriana R Dabkowski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL. Hauptthemen laut MEDLINE: Glioblastoma, Neuroblastoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE In certain cancers, oncogene amplification is correlated with an immunologically cold or noninflamed, tumor immune microenvironment (TIME) and a worse prognosis, for example, in the case of MYCN-amplified neuroblastoma (NBL). However, for other cancer types, the relationship between oncogene amplification and immune response is more complicated or unresolved. One such cancer is glioblastoma multiforme (GBM), in which the epidermal growth factor receptor (EGFR) oncogene is commonly amplified. Unlike MYCN-amplified NBL, EGFR-amplified GBM has not been shown to correlate with a distinct survival probability. METHODS Given this contrasting state for NBL and GBM, we sought to apply a genomics approach to evaluating the immune response for cases with gene amplification. RESULTS Our results confirmed and added further specificity to the cold TIME of MYCN-amplified NBL. Moreover, we demonstrated a novel state of immunologically cold EGFR-amplified GBM tumors. CONCLUSION This approach to using copy number variation and immune receptor recombination read recovery levels to assess gene amplification and TIME, respectively, may be particularly efficient for the rapid evaluation of many other cancer types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaNeuroblastomaHumansDNA Copy Number VariationsN-Myc Proto-Oncogene ProteinErbB ReceptorsOncogenesRecombination, GeneticTumor Microenvironment

Substanzen

N-Myc Proto-Oncogene ProteinErbB Receptors

Autor:innen und Institutionen

  • Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL.
  • Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

ORCID-Profile: Joanna J Song, George Blanck

Zitieren

APA

Dabkowski, T. R., Varkhedi, M., Song, J. J., Gozlan, E. C., & Blanck, G. (2023). Neuroblastoma and Glioblastoma Cases With Amplified Oncogenes Have Reduced Numbers of Tumor-Resident Adaptive Immune Receptor Recombinations. JCO Precision Oncology. https://doi.org/10.1200/po.23.00057

Vancouver

Dabkowski TR, Varkhedi M, Song JJ, Gozlan EC, Blanck G. Neuroblastoma and Glioblastoma Cases With Amplified Oncogenes Have Reduced Numbers of Tumor-Resident Adaptive Immune Receptor Recombinations. JCO Precision Oncology. 2023. doi:10.1200/po.23.00057

BibTeX
@article{Dabkowski2023,
  author = {Dabkowski, Toriana R and Varkhedi, Mallika and Song, Joanna J and Gozlan, Etienne C and Blanck, George},
  title = {Neuroblastoma and Glioblastoma Cases With Amplified Oncogenes Have Reduced Numbers of Tumor-Resident Adaptive Immune Receptor Recombinations},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.23.00057}
}
Kostenlos starten →